Revolymer is an AIM quoted company (registered number 08024489) that designs, develops and formulates novel polymers to improve the performance of its customers’ and partners’ products.

The vision for Revolymer is to build a high growth, high quality margin, specialty materials business based on proprietary polymer technology that provides responsive or smart multi-functional materials. The Board believes that the Company’s technology has broad application.

Revolymer aims to generate growing high quality revenue streams by either licensing its proprietary technologies or through the supply of proprietary products using an outsourced manufacturing model. Current target markets are Household Products, Personal Care and Nicotine Gum.

http://www.revolymer.com/revolymer.html

As of 9 March 2015 Revolymer had been notified of the following holdings comprising more than three per cent of the share capital of the company: subsequent notifications received from major shareholders and PDMRs are shown in the Regulatory Announcements section of the website.


Name

Number of

Ordinary Shares

Percentage of

issued share capital


Woodford Investment Management LLP

10,884,549

19.2%


IP Group

8,385,580

14.8%


Sand Aire

7,099,387

12.6%


Invesco Limited

5,264,451

9.3%


Swarraton Partners

4,953,900

8.8%


Henderson Global Investors

3,470,500

6.1%


Naxos Capital Partners

3,072,980

5.4%


Mr Roger & Mr Sheila Pettman

1,869,047

3.3%

Baillie Gifford & Co
1,784,420

3.2%






3 Sep Panmure Gordon 81.00 Buy
1 Sep Panmure Gordon 93.00 Buy

Market cap of £36M seems overvalued, considering the pretax loss is still very large but the worse yet is only 1M of sells (turnover ).
There is £13.2M cash last December, to soften the cushion, but at this rate will not last long, so better get more contract in.

Revolymer narrows FY pretax loss

Revolymer has narrowed its FY to 31 Dec 14 pretax loss to £4.3m, from a loss of £5.3m. Revenue was £1.0m, from £0.5m. Administrative expenses were the biggest contributor to the losses in both periods.

Lets just see. You said something similar about Fevertree (FEVR) and that has been huge. The share is speculative.

Revolymer PLC (REVO.GB:ISD) set a new 52-week high during today's trading session when it reached 83.40. Over this period, the share price is up 40.41%.

18 Sep Panmure Gordon 81.00 Buy

Directorate Change
RNS
RNS Number : 4455Z
Revolymer PLC
18 September 2015

18th September, 2015

Revolymer plc

Directorate Change



Revolymer plc ("Revolymer" or the "Company"), announces that its Chairman of the Board of Directors ("Chairman"), Mr John "Jack" Keenan, has today retired from this role. After an externally led search process, Dr Bryan Dobson, an existing independent non executive director of Revolymer since 2012, has accepted the role of Chairman, succeeding Mr Keenan with immediate effect. Mr Keenan will remain on the Board as an independent non executive director to provide continuity until a replacement is recruited.

Mr Keenan has been a non executive director of the business since January 2008, and Chairman since the flotation on the AIM Market in July 2012. He has played a significant role throughout this period, applying his considerable experience to guiding the commercial development of the business as well providing advice on corporate governance.

Dr Dobson has extensive expertise in the specialty chemicals industry which is highly relevant to Revolymer's business plan. Specifically, he has nearly 40 years' experience in the chemicals industry, including with ICI plc and Croda International plc. He was a member of the executive management teams in Croda and in a number of large specialty chemicals businesses in ICI, and has extensive management experience running regional and global business units in the UK, US, Belgium and The Netherlands. He also has expertise in developing new business in specialty chemicals sectors; extensive functional experience in R&D and operations and significant M&A experience. Dr Dobson is currently Chairman of Applied Graphene Materials plc, an AIM listed specialty materials business, and a non-executive director of the Newcastle upon Tyne Hospitals NHS Foundation Trust, a major UK teaching hospital.

Kevin Matthews, Revolymer CEO, said "We would like to thank Jack for his valuable advice and guidance to Revolymer over a number of years as Chairman. Looking forward, we are delighted that Bryan has agreed to take up the role of Chairman given his strong track record in the specialty chemicals industry, and look forward to working with him to continue Revolymer's commercial development."

Interim Results
RNS
RNS Number : 5861Z
Revolymer PLC
21 September 2015

21 September 2015

Revolymer plc

Unaudited Interim Results for the 6 month period to 30 June 2015



Revolymer plc (AIM: REVO) ("Revolymer", the "Company" or the "Group"), today announces its unaudited interim results for the 6 month period to 30 June 2015.



Business Highlights

· Deals executed in 2015:

o As announced on 3 June 2015, Revolymer closed a global licence to its encapsulation technology with the international chemicals group Solvay in the field of Sodium Percarbonate ("SPC") for liquid product formulations. Solvay has exclusive rights to apply Revolymer's encapsulation technology to its bleaching active ingredient SPC, commercialised currently by Solvay under the trademark Oxyper®, in the field of liquid formulations of laundry and automatic dish washing. The geographic territory of the licence is global.

o As announced on 1 September 2015, Revolymer closed a licence to its encapsulation technology with OCI Alabama LLC representing the US-headquartered international chemicals group OCI Chemical Corporation ("OCI"). OCI has rights to apply Revolymer's encapsulation technology to its SPC based bleaching active ingredients, commercialised currently by OCI under the Provox C and Provox Ultra (which includes an activator) trademark families, in the field of powder and other solid formulations of laundry, automatic dish wash and other cleaning agents. The geographic territory of the Provox C-based licence is global except for the European Union. The geographic territory of the Provox Ultra-based licence is global.

· The Company has further refined its business model, positioning itself as a specialty chemicals business focussed on controlled release, responsive systems and delivery systems that improve the functional performance of its customers' products, based on its expertise in the design and synthesis of polymers (often in combination with other materials) to manage the interface between different surfaces and phases.

· As announced on 18 September 2015, Bryan Dobson was appointed as Chairman of the Board with immediate effect, replacing Jack Keenan. Mr Keenan will remain as an independent non executive director to provide continuity until a replacement is recruited.



Financial Highlights

· Cash, cash equivalents and short term investments were £12.0m at the period end (30 June 2014: £15.2m, 31 December 2014: £13.2m), benefitting from R&D tax credit receipts of £775k during the period.

· Revenue for the period increased 62% to £594k (2014: £366k) - primarily sales of nicotine gum in Canada to a Canadian retailer.

· Gross profit for the period was £12k (2014: £139k). This reduction is primarily due to the prior period including a release of £157k of deferred sales relating to potential product returns deemed no longer necessary based on actual returns. Gross profit before this release improved by £30k compared to the prior period.

· Administrative expenses for the period reduced to £1.7m (2014: £2.9m), partly due a reduced share based payment charge and a reduction in company overheads. Excluding the share based payment credit/charge, administration expenses were £2.1m (2014: £2.7m)

· Finance income of £48k (2014: £57k) relating to the cash, cash equivalents and short term deposits on hand was credited in the period.

· The loss for the period was £0.3m (2014: loss of £2.7m) after crediting R&D tax credits of £1.3m (2014: £nil) claimed on qualifying expenditure for the three years ended 31 December 2014.






Outlook

The business continues to drive its existing product pipeline towards deals, which management expects will include product supply agreements as well as licences; whilst actively pursuing additional product opportunities in new markets complementary to its expertise.



Dr Kevin Matthews CEO of Revolymer said: "The business has continued to make commercial progress in the period, and also retains significant cash resources on hand to fund future developments. Accordingly we look forward to achieving further milestones as we pursue our focus on improving the functional performance of our customers' products."